Current status and progress of research on CAR-T Cell Therapy for the treatment of hematological malignancies

Chimeric antigen receptor T-cell (CAR-T) therapy, which first entered clinical use in 2010, it has achieved notable advancements in the treatment of blood cancers, leveraging the genetic modification of T cells to identify and destroy cancer cells. Some conditions like acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma can be effective treated with this therapy, this is important because of the premise that various previous therapies have failed. The aim of this therapy is to make T cells express chimeric antigen receptors, a process that requires engineering them, enabling them to specifically recognize tumor antigens, such as CD19. Despite the promising outcomes, challenges remain, this is accompanied by side effects that are more distressing to patients, such as neurotoxicity, as well as limited efficacy in solid tumors. Recent research efforts are focused on optimizing CAR design, enhancing T cell Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advancement in the treatment of hematologic malignancies persistence, and expanding applicability to solid tumors. Developments of bispecific and allogeneic CAR-T cells, and combination therapies are being explored to mitigate current limitations. This review discusses the mechanism of action, clinical applications, and future directions of CAR-T cell therapy, emphasizing its transformative potential and the ongoing efforts to coping with the difficulties of the moment.